Articles
Another Korean company has emerged with an exciting and potentially world-first approach to developing new hair loss therapies using hair follicle organoids. Kangstem Biotech Kangstem Biotech was established in 2010 and has several stem cell therapies in the pipeline for atopic dermatitis, rheumatoid arthritis, and osteoarthritis. Recently, Kangstem Biotech announced an expansion into hair loss…
Hair Cloning Research Expanding There has been no shortage of hair cloning news in the world of late, which is a good thing. In fact, three out of my four recent articles featured different hair cloning treatment modalities. This article will discuss more, and you can expect even more hair cloning news coming soon to…
Published on: Oct 7, 2020 at 20:04
The long awaited phase 2 trial of Hope Medicine’s HMI-115 in androgenetic alopecia has officially begun. HMI-115 Antibody Starts Phase 2 Trial It has almost been two full years since Hope Medicine issued an exciting press release which announced the company’s approval to conduct a phase 2 clinical trial with the US FDA. Since then,…
Follicle Thought is pleased to share an exclusive interview with the CEO of OrganTech as we draw closer to 2024. OrganTech Inc. Resurgence Prior to the year 2020, one researcher’s name was held synonymously with the topic of hair cloning by online hair-seeking communities – Dr. Takashi Tsuji, and most often, just “Tsuji.” The…
TrichoSeeds Co., a biotech founded by Junji Fukuda PhD, has announced a timeline for the start of its hair cloning clinical trial. Note, the snippet above taken from the ko-karie.com website has been edited since the publishing of this article. Luckily, we caught a screenshot of it before the change was made. The…
Epibiotech EPI-001 Approval by the Ministry of Food and Drug Safety Update (12/21/2023) As of December 21st, 2023, Epibiotech has been approved by the Ministry of Food and Drug Safety to start Phase 1/2a clinical trials for its EPI-001 autologous dermal papilla cell treatment to treat androgenetic alopecia. Safety will be measured in Phase 1…
China Trial Enrolls 180 Patients To Complete Enrollment: Update (8/22/23) On August 22, 2023, Kintor Pharmaceutical announced the completion of patient enrollment in a phase 2 trial in China for GT20029. This means all of the patients needed to complete the study have been enrolled, and will undergo their dosing schedule over the next 12…
Seeking Scarless Hair Transplants With Donor Regeneration On July 11th, 2023, Dr. Blake Bloxham completed a verteporfin trial in his New York office. The trial focused on testing verteporfin’s effect on minimizing scarring or potentially producing scarless healing during a hair transplant procedure. Dr. Bloxham treated three different patients undergoing FUT (Follicular Unit Transplantation) hair…
Carmell Therapeutics Merger Finalization Update (09/12/2023) As of September 12th, 2023, Carmell Therapeutics has finalized a merger with a regenerative medicine company called Axolotl Biologix. The company names it a “significant development for the future of regenerative medicine”. Axolotl Biologix is a company that conducts research in regenerative medicines to design and develop human amniotic…